Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07RYM
|
|||
Drug Name |
PMID25666693-Compound-131
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Patented | [1] | |
Inflammatory pain [ICD-11: MG30.42; ICD-10: R52, G89] | Patented | [1] | ||
Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
Osteoarthritis pain [ICD-11: MG30.31] | Patented | [1] | ||
Company |
Sanofi
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H17F4N5O
|
|||
Canonical SMILES |
CNC1=NC=C(C=C1)NC(=O)C2=CC3=CC(=CN=C3N2CC4=CC(=CC=C4)F)C(F)(F)F
|
|||
InChI |
1S/C22H17F4N5O/c1-27-19-6-5-17(11-28-19)30-21(32)18-9-14-8-15(22(24,25)26)10-29-20(14)31(18)12-13-3-2-4-16(23)7-13/h2-11H,12H2,1H3,(H,27,28)(H,30,32)
|
|||
InChIKey |
XTNRHSVPOQBJCX-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [1] |
Target's Patent Info | Transient receptor potential cation channel V1 (TRPV1) | Target's Patent Info | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Inflammatory mediator regulation of TRP channels | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
Reactome | TRP channels |
References | Top | |||
---|---|---|---|---|
REF 1 | Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.